Highlights Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Market Closed - Nasdaq Other stock markets 01:30:00 22/05/2024 am IST			5-day change	1st Jan Change
3.09 ^USD	-1.28%		-15.11%	-46.07%

09/05	Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating	MT
07/05	Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday	05/04	MT
Caribou Gets FDA Clearance For Phase 1 Testing of CB-010 Cell Therapy in Lupus Patients	05/04	MT
Caribou Biosciences, Inc. Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus	05/04	CI
Caribou Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03	CI
Caribou Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	12/03	CI
Caribou Biosciences Says it Reached Alignment With FDA on Phase 3 Trial Plan for Lymphoma Treatment	13/12	MT
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024	13/12	CI
Caribou Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
US FDA Clears Caribou Biosciences' CB-012 Cancer Drug Candidate for Human Study	19/23/19	MT
Caribou Biosciences, Inc. Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	18/23/18	CI
AbbVie Elects to Terminate the Collaboration and License Agreement with Caribou Biosciences, Inc	27/23/27	CI
Caribou Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Caribou Reports Positive Data From Phase 1 Dose Escalation Trial in Non-Hodgkin Lymphoma Patients	14/23/14	MT
Caribou's cell therapy shows promise in early-stage cancer study	14/23/14	RE
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL	14/23/14	CI
Caribou Biosciences Shares Leap 36% After Pfizer Takes Stake	06/23/06	DJ
Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10	CI
Caribou Biosciences, Inc. Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting	17/23/17	CI
Caribou Biosciences' Multiple Myeloma Drug Candidate Granted US FDA's Fast-Track Designation	04/23/04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Highlights

Filters